2 active not recruiting, 2 completed, 1 available, 1 enrolling by invitation. 3 Phase 3, 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 2, Enrolling by invitation 1 |
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Longboard Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) LP352 - Developmental and Epileptic Encephalopathy | Phase 3 | Enrolling by invitation | Longboard Pharmaceuticals | 324 | 2025-02-12 | 2026-10-14 |
| A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) LP352, Placebo - Developmental and Epileptic Encephalopathy | Phase 3 | Active not recruiting | Longboard Pharmaceuticals | 367 | 2024-11-11 | 2026-09-15 |
| A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) LP352, Placebo - Dravet Syndrome | Phase 3 | Active not recruiting | Longboard Pharmaceuticals | 96 | 2024-09-25 | 2026-09-17 |
| Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy LP352, bexicaserin - Developmental and Epileptic Encephalopathy, Dravet Syndrome | Phase 2 | Completed | Longboard Pharmaceuticals | 41 | 2022-11-08 | 2025-12-03 |
| Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies LP352, Placebo - Developmental and Epileptic Encephalopathy, Dravet Syndrome | Phase 1 / Phase 2 | Completed | Longboard Pharmaceuticals | 52 | 2022-03-03 | 2024-11-08 |
| Intermediate-Size Expanded Access Protocol (EAP) for LP352 LP352 - Dravet Syndrome, Lennox Gastaut Syndrome | Available | Longboard Pharmaceuticals | 2025-01-22 |
Epilepsy (6) · Epilepsies, Myoclonic (5) · Lennox Gastaut Syndrome (5) · CDKL5 deficiency disorder (3) · Neurodevelopmental Disorders (3) · Seizures (3) · Tuberous Sclerosis (3)
Australia (6) · United States (6) · Belgium (3) · Brazil (3) · Canada (3) · China (3) · France (3) · Germany (3) · Italy (3) · Japan (3) · Latvia (3) · Mexico (3) · Portugal (3) · Serbia (3) · Spain (3)